Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow HLF by emailGet an email when HLF pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about HLF, unsubscribe in one click. Privacy
📣 What HLF Says Is Next
fourth quarter · “DATED FEBRUARY 18, 2026 Exhibit 99.1 Herbalife Delivers Fourth Quarter and Full-Year Net Sales Growth, Net Sales and Adjusted EBITDA 1 Exceed Guidance Cristiano Ronaldo Invests $7.5 Million in Herbalife’s Pro2col™ Technology LOS ANGELES , February 18, 2026 – Herbalife Ltd. (NYSE: HLF) today reported financial results for the fourth quarter and year ended December 31, 2025: Highlights Fourth Quarter 2025”
Company press release, Feb 18, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full HLF picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for HLF and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.